NCT05055752View on ClinicalTrials.gov

Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers.

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

May 7, 2020

Primary Completion Date

June 29, 2020

Study Completion Date

October 1, 2020

Conditions

Bioequivalence

Interventions

DRUG

Pharmaceutical-lipid aspirin (PL-ASA)

Subjects receive the first drug, followed by a 7-day washout period, then receive the second drug.

Trial Locations (1)

66219

PRA-EDS, Lenexa

Sponsors

Lead Sponsor

All Listed Sponsors

lead

PLx Pharma

INDUSTRY